# A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events

> **NCT07712380** · PHASE2 · NOT_YET_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 450 (estimated)

## Conditions studied

- Cardiovascular Disease

## Interventions

- **COMBINATION_PRODUCT:** Placebo
- **COMBINATION_PRODUCT:** Adjuvanted RZV vaccine
- **BIOLOGICAL:** Adjuvanted RSVPreF3 vaccine

## Key facts

- **NCT ID:** NCT07712380
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2029-05-04
- **Final completion:** 2029-05-04
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2026-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07712380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07712380, "A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07712380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*